ArticleBMJ open2022
Demographic and clinical characteristics associated with variations in antibody response to BNT162b2 COVID-19 vaccination among healthcare workers at an academic medical centre: a longitudinal cohort analysis.
Article in BMJ open, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 40 citations in OpenAlex.
- Impact of vaccine platform and BCG vaccination on antibody responses to COVID-19 vaccination.Frontiers in immunology · 2023Trial
- Pre-existing Comorbidities as Potential Risk Modifiers for New-Onset Myocarditis and Pericarditis following mRNA COVID-19 Vaccination in Males Aged 18-30 in the United States: A Disproportionality Analysis using VAERS Spontaneous Reporting Data.Drugs - real world outcomes · 2026Article
- Impact of Cancer Subtype and Cancer Therapy Exposures on SARS-CoV-2 Outcomes in the Omicron and Subvariant Era.Cancer medicine · 2025Article
- Sex differences in adenosine deaminase activity associate with disparities in SARS-CoV-2 innate immunity.iScience · 2025Article
- SARS-CoV-2 humoral immune responses in convalescent individuals over 12 months reveal severity-dependent antibody dynamics.Communications medicine · 2025Article
- Circulating SARS-CoV-2 spike IgG antibody responses in cancer patients following multiple COVID-19 vaccination boosters.Frontiers in immunology · 2025Article
- Factors Predicting COVID-19 Vaccine Effectiveness and Longevity of Humoral Immune Responses.Vaccines · 2024Review
- Pediatric antibody responses to SARS-CoV-2 after infection and vaccination in Calgary, Canada.BMC infectious diseases · 2024Article
- Article
- Poor immune response to inactivated COVID-19 vaccine in patients with hypertension.Frontiers in medicine · 2024Article
- Non-cross-reactive epitopes dominate the humoral immune response to COVID-19 vaccination - kinetics of plasma antibodies, plasmablasts and memory B cells.Frontiers in immunology · 2024Article
- Factors associated with elevated SARS-CoV-2 immune response in children and adolescents.Frontiers in pediatrics · 2024Article
- Both Humoral and Cellular Immune Responses to SARS-CoV-2 Are Essential to Prevent Infection: a Prospective Study in a Working Vaccinated Population from Southern France.Journal of clinical immunology · 2023Article
- Clinical Utility of SARS-CoV-2 Serological Testing and Defining a Correlate of Protection.Vaccines · 2023Review
- Ethno-demographic disparities in humoral responses to the COVID-19 vaccine among healthcare workers.Journal of medical virology · 2023Article
- Article
- Long-term durability of antibody responses after SARS-CoV-2 vaccination and influencing factors.Journal of internal medicine · 2023Article
- Drug Cocktail Formulation via Circuit Design.IEEE transactions on molecular, biological, and multi-scale communications · 2023Article
- Serological response to vaccination in post-acute sequelae of COVID.BMC infectious diseases · 2023Article
- Association between Gut Microbiota and SARS-CoV-2 Infection and Vaccine Immunogenicity.Microorganisms · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
31 authors at 6 institutions in 1 country.
Funding
Abstract
objectivesWe sought to understand the demographic and clinical factors associated with variations in longitudinal antibody response following completion of two-dose regiment of BNT162b2 vaccination.
designThis study is a 10-month longitudinal cohort study of healthcare workers and serially measured anti-spike protein IgG (IgG-S) antibody levels using mixed linear models to examine their associations with participant characteristics.
settingA large, multisite academic medical centre in Southern California, USA.
participantsA total of 843 healthcare workers met inclusion criteria including completion of an initial two-dose course of BNT162b2 vaccination, complete clinical history and at least two blood samples for analysis. Patients had an average age of 45±13 years, were 70% female and 7% with prior SARS-CoV-2 infection.
resultsVaccine-induced IgG-S levels remained in the positive range for 99.6% of individuals up to 10 months after initial two-dose vaccination. Prior SARS-CoV-2 infection was the primary correlate of sustained higher postvaccination IgG-S levels (partial R
conclusionsWhile the IgG-S antibody response remains in the positive range for up to 10 months following initial mRNA vaccination in most adults, determinants of sustained higher antibody levels include prior SARS-CoV-2 infection, female sex, younger age and absence of hypertension. Certain determinants of the longitudinal antibody response appear significantly modified by prior infection status. These findings offer insights regarding factors that may influence the 'hybrid' immunity conferred by natural infection combined with vaccination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.